StackTerminal.Health

BETA

Lutein + Zeaxanthin

Supported by AREDS2 context for AMD progression risk reduction when used as part of a specific formula in at-risk populations.

womens-healthlongevityimmune-support
Evidence last reviewed: 04 Apr 2026
Buy this ingredient← Back
Supplement note
Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Sign in to keep a private note on Lutein + Zeaxanthin.
Sign in
Evidence
2 records
AMD progression to advanced AMD — primary RCT results
Adults aged 50–85 at risk for advanced AMD (n=4,203) • Randomized clinical trial (AREDS2)
PUBMEDModerate

The AREDS2 primary report found lutein 10 mg + zeaxanthin 2 mg did not significantly reduce progression to advanced AMD vs placebo overall; however, secondary analyses showed lutein/zeaxanthin reduced risk in participants with the lowest dietary intake of these carotenoids. Long-term 10-year follow-up (AREDS2 Report 28) found HR 0.91 (95% CI 0.84–0.99) favoring lutein/zeaxanthin.

Dose: 10 mgDuration: Median ~5 years
Citation: Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005-2015.
AMD progression risk modification (AREDS2 context)
Adults at risk for advanced AMD • Large randomized clinical trial program
PUBMEDModerate

NEI summaries describe AREDS2 testing lutein/zeaxanthin additions & related outcomes in AMD risk contexts.

Dose: 12 mgDuration: Long-term (trial program)
Citation: NIH NEI – About AREDS/AREDS2 clinical trials
Forms
Capsule
Often 10 mg lutein + 2 mg zeaxanthin in AREDS2-style formulas

Stacks containing Lutein + Zeaxanthin

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.